The key goal of the research project is to develop novel drugs and degrader molecules to target survival pathways in aggressive lymphomas (DLBCL). The project is based on our previous work discovering new drug target candidates that are highly relevant for DLBCL biology. Your primary responsibility will involve optimizing and developing the lead drug candidates, as well as contributing to structure-activity relationship studies in Prof. Knapp's lab. You will work in close collaboration with the Oellerich lab for the validation of the compounds and to study drug resistance mechanisms. You will work in an interdisciplinary environment. This project will cover a plethora of cutting-edge techniques from both collaboration partners including CRISPR/Cas9 screens and quantitative proteomics, protein biochemistry, structural biology and novel biochemical and biophysical and cell based screening methods.